Handelsavisen
prelaunch
Companies ›Healthcare ›HEAL.CD
HE
HEAL.CD — — Biotechnology

Restart Life Sciences Corp

$0,09
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
5,3M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-208,6 %
Net margin
—
Debt / equity
0,19
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Restart Life Sciences Corp is a biotechnology company operating in the Health Care sector, though specific revenue-generating activities or product lines are not detailed in the available financial snapshot.

Business. Restart Life Sciences Corp (HEAL.CD) is a biotechnology company operating within the Health Care sector. The firm is engaged in biotechnology activities and is listed under the ticker HEAL.CD. Specific details regarding its operating segments, headquarters location, and primary exchange are not provided in the available data. Consequently, the company is described at the industry level as a biotechnology entity.

Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-208,6 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning HEAL.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to HEAL.CD. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Restart Life Sciences Corp (HEAL.CD) is a biotechnology company operating within the Health Care sector. The firm is engaged in biotechnology activities and is listed under the ticker HEAL.CD. Specific details regarding its operating segments, headquarters location, and primary exchange are not provided in the available data. Consequently, the company is described at the industry level as a biotechnology entity.

    Classification85 %
    SectorHealth Care
    Industry groupBiotechnology
    AI synthesis
    GENERATED
    — missing data
    Key takeaways
    • The company holds a strong liquidity position with a current ratio of 3.67 and cash reserves exceeding total liabilities.
    • Significant unprofitability is evident with a net loss of CAD 1.39 million and negative returns on equity and assets.
    • Low leverage is maintained with a debt-to-equity ratio of 0.19, reducing financial distress risk.
    • Valuation multiples are distorted by negative earnings, with a P/B of 4.12 suggesting market optimism despite current losses.
    • No segment or geographic revenue data is available to assess business diversification.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    $0,09
    Market cap
    $5.3M
    Enterprise valueⓘ
    $3.9M
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    4.1x
    P / Tangible bookⓘ
    4.1x
    Tangible book
    $1.3M
    Net cashⓘ
    $1.4M
    Current ratioⓘ
    3.7
    Debt / equityⓘ
    0.2
    ROAⓘ
    -1.5%
    ROEⓘ
    -2.1%
    Cash conversionⓘ
    72.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-208,6 %Bottom quartile
    D/E0,19Bottom quartile
    Cash Conv0,72Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Reference data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Price To Tangible Book
      market_price / (tangible_book_value / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Return On Equity
      net_income / total_equity
    • Enterprise Value
      market_cap - net_cash
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • Restart Life Sciences Corp Market data — financials · 2026-07-22

    Ownership & reference

    Leadership

    • Derek IvanyExecutive Chairman of the Board
    • Steve LoutskouPresident, Chief Executive Officer, Director

    Insider activity

    — missing data

    Short positioning

    22.7Kshares short+67.9% vs prior
    3.17days to cover
    32.4%short of daily vol
    13fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    HEAL.CDCanonical
    — · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage